Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to investigate the long-term feasibility of the new Provox Vega 22.5 voice prosthesis (outer diameter of 22.5 French) and its insertion system (SmartInserter) in laryngectomized patients who currently use a Provox2 voice prothesis.


Clinical Trial Description

Nowadays, many laryngectomized patients use a voice prosthesis to speak. The Provox2 is an indwelling voice prosthesis that has been on the market since 1997. Recently a new Provox voice prosthesis has been developed, the Provox Vega. This prosthesis is available in 3 different outer diameters. In this study the device with an outer diameter of 22.5 French is tested. The Provox Vega 22.5 is the successor of the Provox2 voice prosthesis. Both prostheses have an outer diameter of 22.5 French.

Outcomes were recorded by means of patient questionnaires and device life.

It is expected that some patients will like the new device (Provox Vega 22.5) better than the old one (Provox2) because the airflow resistance for speaking of the new prosthesis is lower when measured in a laboratory. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT00884910
Study type Interventional
Source Atos Medical AB
Contact
Status Completed
Phase Phase 2
Start date February 2008
Completion date March 2010

See also
  Status Clinical Trial Phase
Completed NCT04491487 - Pre-operative Counselling in Laryngectomized Patients N/A
Terminated NCT01948219 - ENTegral Artificial Larynx Clinical Trial N/A
Completed NCT02601638 - Laryngectomy Education N/A
Recruiting NCT05489965 - Gender Disparities in Voice Outcomes After Tracheoesophageal Puncture in Total Laryngectomy Patients (UC Davis)
Recruiting NCT04650919 - Aortic Laryngeal Rehabilitation Graft N/A
Terminated NCT00661570 - Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis Phase 2
Completed NCT02739958 - Effects of Propofol-dexmedetomidine on Immune Function in Patients With Cancer Larynx N/A
Completed NCT00942903 - Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy Phase 1
Completed NCT00743262 - Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis Phase 1/Phase 2